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Biological function  
Monocyte chemoattractant protein-1 (MCP-1) (also known as CCL2) is a member of large family of 
chemotactic cytokines (chemokines) known to be important soluble mediators of innate immunity 
and tissue inflammation. MCP-1 was one of the earliest cytokines found to have a selective role in 
controlling monocytes/macrophage migration (although it is now known to act also on T cells and 
basophils). This is in contrast to other inflammatory mediators, such as complements and platelet 
activity factor (PAF), which have a broader chemoattractant activity. 
 
Origin and regulation of renal MCP-1  
MCP-1 is synthesised by a range of cell types in the kidney including intrinsic kidney cells and 
infiltrating leucocytes (Figure 1A). Glomerular mesangial cells release MCP-1 in vitro following 
stimulation with a variety of stimuli include inflammatory cytokines (IL-1 and TNFɲ), immune 
complexes, metabolic factors (glucose, glycation end products), danger associated molecular patterns 
(DAMP), such as extracellular ATP [1]. Podocytes release MCP-1 following stimulation with glycation 
end products, TNFɲ and TGF-ɴ in vitro [2-4]. Stimulation of podocytes (which express CCR2) by MCP-
1 has also been shown to downregulate nephrin, an alteration that could contribute to development 
of proteinuria in diabetic nephropathy and FSGS [5]. Renal tubular cells also produce MCP-1 in 
response to IL-1 and TNF [6], thrombin [7], and albumin [8] . The wide variety of cells and stimuli that 
are known to release and respond to MCP-1 highlight its importance but also raise questions as to 
whether it could ever be useful as a specific disease biomarker or selective therapeutic target (recently 
reviewed) [9]. 
 
Ligand receptor relationships 
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Although MCP-1 and CCR2 is the best-known ligand-receptor interaction, it is not an exclusive one.  
MCP-1 has been shown to interact with multiple receptors ie CCR1, CCR2, CCR3 and CCR5. Conversely, 
CCR2 can bind to other chemokines apart from MCP-1 such as CCL7, CCL8, CCL11, CCL12, CCL13, CCL24 
and CCL26 (Figure 1B). Therefore, selective CCR2 blockade should not be considered the same as MCP-
1 neutralisation (with an anti-MCP-1 antibody). Nevertheless, the severity of kidney injury 
(macrophage infiltration, type I collagen expression and tubulointerstitial fibrosis) was reduced in Ccr2 
knockout mice or following treatment with a CCR2 antagonist [10] suggesting that CCR2 could be the 
major receptor mediating the effect of increased MCP-1 in kidney disease. 
 
/ŶƚŚŝƐŵŽŶƚŚ ?ƐŝƐƐƵĞŽĨEd ?ƚŚƌĞĞƉĂƉĞƌƐŚŝŐŚůŝŐŚƚƚŚĞƌŽůĞŽĨDW-1 in a range of kidney diseases 
both as a clinical biomarker of disease activity or in disease pathogenesis. The first two studies report 
that the combination of urinary MCP-1 (uMCP-1) with other soluble mediators can improve its 
performance as a biomarker of disease activity. In the first study, Moran and colleagues found that 
the combination of urinary soluble CD163 (sCD163) and uMCP-1 improved the diagnostic accuracy of 
renal flares in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis [11]. In 
the second study, Wu and colleagues report a significant association between urinary epidermal 
growth factor (uEGF) and uMCP-1 with disease progression in diabetic nephropathy [12]. Finally, 
Wilkening and colleagues demonstrate increased expression of the MCP-1 receptor CCR2 in kidney 
biopsies of patients with focal segmental glomerulosclerosis (FSGS) and found a positive effect of CCR2 
deletion in a murine model of FSGS [13]. 
 
Expression of MCP-1 in kidney diseases (Table 1)  
Immune mediated diseases 
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Increased glomerular synthesis of CC chemokines, including MCP-1, has been shown to correlate with 
monocyte/macrophage infiltration in experimental models of antibody and immune complex 
mediated glomerulonephritis [14, 15] . In clinical diseases, increased MCP-1 expression in human renal 
biopsies and excretion in urine has been detected in a number of proliferative glomerulonephritis 
associated with monocyte/macrophage infiltration, such as IgA nephropathy, lupus nephritis, renal 
ǀĂƐĐƵůŝƚŝƐĂŶĚ'ŽŽĚƉĂƐƚƵƌĞ ?ƐĚŝƐĞĂƐĞ [16, 17].  
In inflammatory diseases, the long-term effects of renal injury are determined by a balance between 
inflammation-induced injury and cellular repair or regeneration. Epidermal growth factor (EGF) is 
produced by ƚŚĞƚŚŝĐŬĂƐĐĞŶĚŝŶŐůŝŵďŽĨ,ĞŶůĞ ?ƐůŽŽƉĂŶĚdistal renal tubule and has tubular-trophic 
effects.  In a study of patients with IgA nephropathy, Torres and colleagues found that the 
uEGF/uMCP-1 ratio provided a better prognostic assessment of renal outcome at 4 and 8 years after 
biopsy than the uEGF/creatinine or uMCP-1/creatinine ratio [18]. 
The role of uMCP-1 as a disease marker has also been investigated in ANCA associated renal vasculitis. 
In an early study, uMCP-1 was found to be elevated in patients with active renal vasculitis but not in 
patients with systemic vasculitis sparing the kidney. Most patients had a decrease in uMCP-1 following 
successful broad immunosuppressive treatment except interestingly in one patient who had further 
rise in uMCP-1 and progressed to renal failure despite immunosuppressive treatment [17]. Although 
the number of patients reported in this initial study was small, these findings have since been 
replicated by several other groups [19-21]. Recently, uMCP-1 has also been used successfully as a pre-
specified secondary endpoint in a randomised clinical trial of a complement C5a receptor inhibitor in 
patients with ANCA associated renal vasculitis [22].  
In the latest study by Moran and colleagues, the combination of creatinine-normalised urinary soluble 
CD163 (usCD163) and uMCP-1 was more sensitive than either alone in detecting subtle renal flares in 
ANCA associated renal vasculitis (n=88) in the longitudinal VCRC (Vasculitis Clinical Research 
Consortium) multicentre North American cohort [11]. Mechanistically, this could reflect distinct 
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independent aspects of macrophage activation (CD163) and recruitment (MCP-1) since there was a 
poor correlation between them. The algorithm performed better when new-onset proteinuria was 
included as an independent variable. A major limitation of the study is the reliance on clinical 
assessment alone without histological confirmation leading to potential misclassification. There was 
also a discrepancy with uMCP-1 results reported on a subset of patients with non-renal disease by a 
different group [20]. Finally, although the post-test probabillity of detecting a positive renal flare using 
this algorithm was >90% in patients with either moderate or high pre-test probability of having a renal 
flare, the equivalent post-test probability of a negative test excluding a flare was 22% (moderate) or 
58% (high) respectively indicating that the proposed algorithm will need much refinement and 
validation prior to clinical use.  
Of interest, MCP-1 may also play a role in the pathogenesis of chronic allograft failure. In a recent 
study, uMCP-1 was prognostic of renal allograft failure [23]. 
 
Diabetic nephropathy 
Although diabetic nephropathy is now the most common cause of kidney failure, the contribution of 
monocytes/macrophages in its pathogenesis has not been studied until recently. In renal biopsies of 
patients with diabetic nephropathy, increased expression of MCP-1 and macrophage infiltration in the 
glomeruli and tubulointerstitium has been reported. Similarly, increased numbers of glomerular 
macrophages have been detected in rodent models of diabetic nephropathy [24]. Proteinuria and 
glomerular macrophages were significantly reduced in Mcp1 knockout mice following the 
experimental induction of diabetes. Increased levels of uMCP-1 as well other cytokines and profibrotic 
growth factors (TGF-ɴ, CTGF) have been detected in patients with diabetic nephropathy. In a 
longitudinal study over 6 years, the uMCP-1/creatinine ratio (uMCP-1/Cr) was found to be predictive 
of the rate of eGFR decline [25]. These results have been validated in several other studies even when 
adjusted for baseline covariates, such as diabetic control, blood pressure, age and sex [26].  
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The idea of measuring the uEGF/uMCP-1 ratio was first described in a study of IgA nephropathy [18]. 
Two later studies (including one in this current issue) have now demonstrated the prognostic value of 
uEGF/uMCP-1 in diabetic nephropathy [12, 27]. The first study from the Joslin Diabetic Centre 
reported a negative correlation between uEGF/Cr and uEGF/uMCP-1 and the occurrence of diabetic 
kidney disease [27]. In longitudinal follow up, the uEGF/uMCP-1 ratio correlated more closely to the 
rate of loss of eGFR than uEGF/Cr or uMCP-1/Cr. When a composite end point (end stage kidney 
disease or 30% reduction in baseline eGFR) was studied, uEGF/Cr and uEGF/uMCP-1 were negative 
predictors whereas uMCP-1/Cr was an independent positive predictor of disease progression [27]. In 
this issue, Wu and colleagues confirm that the ratio of uEGF/uMCP-1 in the urine is a better prognostic 
biomarker than the uEGF/Cr or uMCP-1/Cr ratio [12]. However, there are several major limitations to 
the current study. First, the conclusions were based on a cross-sectional analysis of two very different 
Chinese population-based cohorts with early (INDEED, n=1811) and advanced (C-STRIDE, n=208) 
diabetic kidney disease (DKD). Second, over 90% of patients had Type 2 diabetes mellitus and 
therefore the conclusions may not apply to Type 1 patients. Third, although statistically significant, 
the use of uEGF/Cr or uEGF/uMCP-1 only marginally added to the discriminatory value of urine 
albumin creatinine ratio (uACR) is distinguishing DKD from those without DKD in the INDEED cohort. 
Similarly, uEGF/Cr, uMCP-1/Cr or uEGF/uMCP-1 showed limited clinical value (overlapping confidence 
intervals) in predicting composite kidney outcomes (end-stage renal failure and 30% decline in eGFR) 
in the C-STRINE cohort. Although promising, these results will clearly need to be validated in a larger 
multi-ethnic cohort with longer term follow-up. 
The clinical relevance of the MCP-1/CCR2 pathway has been tested in a trial of CCX140B, a small 
molecule inhibitor of CCR2, in type 2 diabetic patients with well-controlled blood pressure (average 
age 62.5, women 15%, ethnic origin 97% Caucasian, average BP 137/78 blood pressure, average eGFR 
62 ml/min/1.73 m2) and receiving maximal tolerable dose of angiotensin converting enzyme inhibitor 
or angiotensin receptor inhibitor. Low dose, but not high dose, treatment with CCX140B resulted in a 
significant reduction in urinary albuminuria in comparison to placebo [28]. However, the clinical 
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development of CCX140B requires further evaluation because of the lack of efficacy of high dose 
treatment. In a Phase 2A clinical trial in type 2 diabetic patients, a different CCR2 antagonist, 
Emapticap pegol (NOX-E36), was studied. Although the drug was safe and well tolerated, the reduction 
in albuminuria (29% treated v 16% placebo) observed did not reach significance in comparison to the 
placebo treatment [29]. 
 
Focal segmental glomerulosclerosis (FSGS) 
Increased uMCP-1 had been previously reported in patients with FSGS [30] and increased renal tubular 
expression of MCP-1 was detected in FSGS renal biopsies [6]. Wilkening and colleagues now show that 
there is increased gene expression for MCP-1 and CCR2 in microdissected FSGS human glomeruli. This 
is an interesting finding since FSGS is not a typical proliferative glomerulonephritis [13]. However, 
these results were based on microarray analysis without validation by other techniques. The authors 
did not determine the intrinsic glomerular cell types expressing MCP-1 and CCR2 in diseased glomeruli. 
However, they did show that soluble urokinase-type plasminogen activator receptor (suPAR) and 
recombinant TNFɲ stimulated podocytes to produce MCP-1 in vitro. Importantly, their study 
demonstrated that genetic deletion of CCR2 in the adriamycin-induced murine FSGS model reduced 
macrophage numbers in the glomeruli and tubulointerstitium, and simultaneously reduced the 
severity of glomerular and tubulointerstitial fibrosis [13]. 
 
Other chronic kidney diseases 
Increased renal tubular expression of MCP-1 has been detected in the renal biopsies of patient with a 
variety of glomerulonephritis (IgA nephropathy, membranous nephropathy, membranoproliferative 
glomerulonephritis and FSGS) in close proximity to infiltrating monocytes/macrophages [31]. 
Furthermore, inflammatory cytokines such as IL-1 and TNF are capable of stimulating cultured renal 
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tubular epithelial cells to release MCP-1 [6].  In another study of patients with a range of kidney 
diseases (including thin glomerular basement disease, IgA nephropathy, ischaemic/hypertensive 
nephropathy, FSGS, membranous nephropathy, diabetic nephropathy, minimal change nephropathy, 
primary amyloidosis, light-chain nephropathy), uMCP-1 was shown to correlate with the number of 
interstitial macrophages [30] (Table 1). This suggests that diseases of diverse aetiology may share a 
final common pathway for disease progression characterised by monocyte/macrophage infiltration 
and chronic tubulointerstitial injury. 
Of interest, the uMCP-1/Cr ratio was found to be elevated in patients with congenital obstructive 
nephropathy and surprisingly improved following surgical treatment [32]. Unexpectedly, very high 
levels of uMCP-1 were also detected in patients with Fanconi syndrome due to ĞŶƚ ?ƐĚŝƐĞĂƐĞ ? >ŽǁĞ ?Ɛ
syndrome and autosomal-dominant idiopathic Fanconi syndrome [33]. It is unclear whether these high 
levels relate to increased local tubular synthesis or decreased tubular reabsorption of filtered MCP-1.  
 
Polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD) is the third or fourth most common cause of 
kidney failure world-wide [34]. The major research focus in ADPKD research has been on 
understanding how increased tubular cell proliferation and fluid secretion lead to cyst growth. 
Nonetheless, there is now increasing evidence that other factors (including metabolism, autophagy, 
inflammation and innate immunity, oxidative stress, epigenetic modification) could contribute to the 
severity of disease progression in ADPKD (recently reviewed [35]) . 
Although ADPKD is not an obvious disease associated with monocyte/macrophage infiltration, early 
data from experimental models had indicated a modifying role for MCP1 in disease pathogenesis. 
Increased renal expression of MCP-1 was detected and localised to the cyst-lining epithelium in a non-
orthologous rat PKD model (Han:SPRD), [36] and in murine Pkd1 models [37]. Significantly tubule-
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specific deletion of Mcp1 or administration of a CCR2 inhibitor to Pkd1 mutant mice reduced the 
number of pericystic macrophages, cyst formation, tubular injury and improved kidney function [38]. 
MCP-1 has also been detected in renal cyst fluid, cyst lining of end-stage ADPKD kidneys and in urine 
(but not serum) samples of ADPKD patients indicating de novo tubular synthesis [39]. Importantly, 
uMCP-1 levels were positively correlated with the rate of loss of eGFR in another study [40]. In the 
pivotal TEMPO3/4 trial in patients with ADPKD, there was a 11-24% reduction in uMCP-1 over 36 
months in the tolvaptan-treated group [41] raising the possibility that MCP-1 could be a biomarker of 
therapeutic response in ADPKD trials. 
 
Challenging issues in blocking MCP-1 and CCR2 
In the CCX140B trial in type 2 diabetic patients with nephropathy, blocking CCR2 resulted in a dose-
dependent increase in plasma MCP-1 in comparison to the placebo group [28]. Only the lower dose of 
the CCR2 blocker reduced albuminuria significantly. The increase in plasma MCP-1 observed at the 
higher dose could have led to an increase in systemic inflammation counter-balancing the beneficial 
effects on renal inflammation observed at the lower dose.  
Conversely, the systemic delivery of MCP-1 inhibitor or a neutralisation antibody could increase the 
concentration gradient between circulating plasma and tissue levels paradoxically leading to increased 
leukocyte recruitment. In addition, circulating antibody-MCP-1 immune complexes may still retain 
biological activity. These potential issues have been highlighted by results of a phase 2 clinical trial of 
a human monoclonal antibody (mAb) to MCP-1 (ABN912) in rheumatoid arthritis [42]. After two 
infusions of ABN912, no clinical benefits were observed in the treated patients. However there were 
very high serum levels of ABN912-MCP-1 immune complexes and synovial biopsies showed that the 
group treated with the highest dose of anti-MCP-1 mAb showed a paradoxical rise in the number of 
CD68+ macrophages in the synovium lining [42].  
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Future perspectives 
uMCP-1 has unexpectedly emerged as a sensitive biomarker of disease activity in a range of kidney 
diseases, not just in those characterised by acute inflammation but also in others of a more chronic 
nature. The latter observation thus supports a disease-modifying role for chronic inflammation due to 
monocyte/macrophages in a common pathway of renal disease progression regardless of the initial 
aetiology. Definitive proof of this hypothesis is awaited since to date, clinical trials attempting to block 
MCP-1 action (through CCR2 blockade) in diabetic nephropathy have been equivocal, possibly due to 
the redundancy of ligand-receptor interaction and/or unanticipated effects on systemic MCP-1 levels. 
Nonetheless, based on our emerging knowledge of disease pathogenesis, it seems likely that a 
combinatorial therapeutic approach targeting several key cytokines apart from MCP-1 in chronic 
kidney disease will be required. Other chemokines with powerful chemoattractant effects on 
monocytes/macrophages (such as RANTES, MIP-1ɲ and MIP-1ɴ) as well as pro-fibrotic cytokines (TGF-
ɴ, CTGF) have been shown to be upregulated in preclinical and clinical studies. The simultaneous 
analysis of multiple urinary chemokines, including MCP-1 using multiplex assays is now achievable and 
may add to the utility of uMCP-1 as a prognostic, activity or therapeutic biomarker. 
These three papers add to the emerging body of evidence that uMCP-1, probably in combination with 
other soluble mediators (such as CD163, EGF and others), could be a clinically useful biomarker for 
disease onset or progression in acute and chronic kidney disease from multiple aetiologies. Future 
studies in larger multi-ethnic longitudinal patient cohorts should clarify whether it is a sufficiently 
sensitive biomarker especially for chronic kidney disease. Whether inhibiting MCP1 synthesis or action 
is beneficial in any form of kidney disease in man remains to be shown.  
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Legend to Figure 1 
The renal MCP-1 and CCR2 axis 
A. Cytokines, inflammatory cells & the pathogenesis of kidney disease. MCP-1 can be synthesised by 
a range of cell types including macrophages, podocytes, mesangial cells, endothelial cells and tubular 
cells. 
B. The interaction between MCP-1 and CCR2 is not exclusive as MCP-1 can also bind to CCR1, CCR3 
and CCR5. Conversely, CCR2 has been shown to bind multiple chemokines such as CCL7, CCL8, CCL11, 
CCL12, CL13, CCL24 and CCL26. 
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Table 1: Urinary and renal MCP-1 as a biomarker in studies of patients with kidney disease 
Diagnosis Clinical correlation N Response to treatment and 
Prognosis 
Reference 
Crescentic GN 
due to ANCA and 
IgAN 
uMCP-1 correlated 
with glomerular 
crescents and 
CD68+ cells in the 
interstitium 
20 uMCP-1 fell in response to 
corticosteroid treatment 
[43] 
IgA nephropathy uMCP-1 higher 
than controls 
5  [16] 
Lupus Nephritis uMCP-1 higher 
than controls 
3  [16] 
IgA nephropathy uEGF/uMCP-1 ratio 132 Lower uEGF/uMCP-1 correlated 
with more severe renal 
histopathology. 
Lower uEGF/uMCP-1 prognostic 
of worse renal survival over 4 
and 8 years 
[18] 
ANCA associated 
renal vasculitis 
uMCP-1 raised in 
patients with 
active renal 
vasculitis 
52 uMCP-1 fell in response to 
immunosuppression except in a 
non-responder. 
Rising uMCP-1 in one patient 
who progressed to ESRD  
[17] 
ANCA associated 
vasculitis 
Raised uMCP-1 in 
patients is 
prognostic of 
future relapse 
99  [19] 
ANCA associated 
vasculitis 
Raised uMCP-1 in 
both renal flare 
and some cases of 
50% of non-renal 
flares 
50  [20] 
ANCA associated 
vasculitis 
Comparison of 161 
biomarkers: 
uMCP-1 and CRP 
are the best 
biomarker to 
distinguish 
between active 
disease and 
remission 
22  [21] 
ANCA associated 
renal vasculitis 
uMCP-1 as a 
secondary 
endpoint of the 
clinical trial 
67 Fall in response to 
immunotherapy (including 
corticosteroid +/- C5a receptor 
inhibitor 
[22] 
ANCA associated 
renal vasculitis 
Combined uMCP-
1/Cr, uCD163/Cr 
and new onset 
proteinuria were 
effective in 
88  [11]  
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identifying patients 
with active renal 
vasculitis 
Diabetic 
nephropathy 
uMCP-1 correlated 
with late stage 
diabetic 
nephropathy, with 
increased number 
of CD68+ 
macrophages on 
renal biopsies. 
MCP-1 positive 
cells were detected 
in the 
tubulointerstitium 
45  [24] 
Diabetic 
nephropathy 
uMCP-1 raised in 
patients with 
established 
macroalbuminuria 
43 Rate of loss of eGFR over 6 
years 
[25] 
Diabetic 
nephropathy 
Subsets of Patients 
from ACCORD 
study 
Baseline and year 2 
uMCP-1 
380 Prognostic of rate of loss of 
eGFR over 5 years 
[26] 
Diabetic 
nephropathy 
uEGF/MCP-1 is 
prognostic of eGFR 
1032  [27] 
Diabetic 
nephropathy 
uEGF/MCP-1 
negatively 
associated with 
onset or 
progression of DKD 
1811 Two cohorts with early 
(INDEED) or advanced DKD (C-
STRINE). Negative correlation 
with incidence of DKD or renal 
survival using composite 
endpoint (end stage renal 
disease or 30% reduction eGFR 
[12] 
FSGS Increased 
expression of 
mRNA for MCP-1 
and CCR2 
10  [13] 
A range of kidney 
diseases 
uMCP-1 correlated 
with the number of 
interstitial 
macrophage  
215 
(30 
patients 
with 
FSGS) 
 [30] 
Obstructive 
uropathy due to 
pelviureteric 
junction 
obstruction 
Inverse 
relationship to 
kidney function 
(MAG3) 
24 Reduction of uMCP-1 after 
pyeloplasty 
[32] 
Inherited renal 
Fanconi 
syndrome 
Raised uMCP-1 in 
all the patients 
with inherited 
10  [33] 
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renal Fanconi 
syndrome 
ADPKD Correlated with 
Serum creatinine 
concentration 
55  [39] 
ADPKD Total kidney  
volume correlated 
with the amount of 
uMCP-1 
102  [44] 
ADPKD Higher uMCP-1 in 
comparison to 
normal subjects 
1307 Reduction of uMCP-1 in 
patients treated with Tolvaptan 
[41] 
ADPKD uMCP-1 correlated 
with annual rate of 
loss of eGFR 
104  [40] 
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